Share on LinkedInShare on LinkedIn

ARTICLE · 12 MAY 2017

Federal Circuit Interprets The Post-AIA On-Sale Bar

On May 1, 2017, the U.S. Court of Appeals for the Federal Circuit issued an opinion in Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc. that considered the America Invents Act...

United StatesIntellectual Property

On May 1, 2017, the U.S. Court of Appeals for the Federal Circuit issued an opinion in Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc. that considered the America Invents Act ("AIA")'s changes to the on-sale bar rule of 35 U.S.C. § 1021. Specifically, the Court addressed the extent to which an alleged sale must be made "public" in order to trigger application of the on-sale bar post-AIA. Based on the particular facts of this case, the Court found that a purchase and sale agreement that was publicly disclosed satisfied the post-AIA on-sale bar, even though the public disclosure did not include all of the details about the claimed invention.

Before Congress enacted the AIA, § 102 barred the patentability of an invention that was "patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent."2 The AIA amended § 102, so that it now bars the

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from